ストックスクリーナーアプリを入手
72.22
0.52%
-0.38
アフターアワーズ：
71.14
-1.08
-1.50%
前日終値:
$72.60
開ける：
$72.52
24時間の取引高:
4.17M
Relative Volume:
0.84
時価総額：
$223.91B
収益：
$54.07B
当期純損益:
$7.04B
株価収益率:
32.03
EPS:
2.255
ネットキャッシュフロー:
$7.28B
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
-5.24%
6か月 パフォーマンス:
-9.25%
1年 パフォーマンス:
+7.79%
1日の値動き範囲:
$72.05
$72.84
1週間の範囲:
$72.05
$74.19
52週間の値動き範囲:
$62.75
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
名前
Astrazeneca PLC
セクター
電話
44 20 3749 5000
住所
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
72.22 | 223.91B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca PLC (AZN) 最新ニュース
AstraZeneca remains top pick with leading American bank. Here's why - Proactive Investors
How Spain Became Big Pharma’s New Hotspot in Europe - Bloomberg.com
AstraZeneca PLC ADR falls Tuesday, underperforms market - MarketWatch
AstraZeneca Keeps Generics Off Shelves Ahead Of Appeal - Law360
AstraZeneca reports total voting rights - Investing.com
Peering Into AstraZeneca's Recent Short Interest - Benzinga
Baxdrostat, AstraZeneca’s Next Big CVRM Bet - insights.citeline.com
AstraZeneca Announces Share Capital and Voting Rights Update - TipRanks
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication - Yahoo
428,441 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Brandywine Global Investment Management LLC - MarketBeat
A £10,000 investment in AstraZeneca shares last Christmas is now worth… - Fool UK
AstraZeneca: 'AZD0780' promising against cholesterol - MarketScreener
Pictet Asset Management Holding SA Sells 53,904 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s (AZN LN) Potential Blockbuster Pill Halves High Cholesterol - Bloomberg.com
Congress Wealth Management LLC DE Raises Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients - AOL.com
AstraZeneca Says Investigational Drug Cuts LDL Cholesterol in Phase 2b Trial - MarketScreener
AstraZeneca’s potential blockbuster pill halves high cholesterol - The Detroit News
AstraZeneca reports cholesterol drug success in trial By Investing.com - Investing.com UK
AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win - insights.citeline.com
AstraZeneca’s Calquence Nears EU Approval for Mantle Cell Lymphoma - Investing.com
AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval - MarketScreener
Astrazeneca Receives Approval Recommendation for Calquence Combination Therapy in Europe - MarketScreener
FDA approves AstraZeneca’s Imfinzi for bladder cancer - Investing.com
FDA approves AstraZeneca’s Imfinzi for bladder cancer By Investing.com - Investing.com UK
FDA approves AstraZeneca’s IMFINZI for bladder cancer By Investing.com - Investing.com UK
AstraZeneca makes regulatory progress with Imfinzi, Calquence - ShareCast
AstraZeneca Scores Key Regulatory Wins in US, EU for Cancer Treatments - Marketscreener.com
AstraZeneca PLC : A technical turn-around configuration - MarketScreener
AstraZeneca's Calquence Combo Gets Positive Opinion from EU Panel for Rare Blood Cancer - Marketscreener.com
Astrazeneca's Calquence Recommended For EU Approval In 1L MCL - Marketscreener.com
AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer - DirectorsTalk Interviews
Imfinzi by AstraZeneca gets US approval for bladder cancer treatment - Investing.com UK
J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - MSN
AstraZeneca - britannica.com
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding - GlobeNewswire Inc.
AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1 - Medical Dialogues
AstraZeneca's Imfinzi gains additional indication for bladder cancer - Seeking Alpha
AstraZeneca (AZN) Gains FDA Approval for New Imfinzi Indication - GuruFocus
Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca Sues Consultancy For £32M Over HQ Defects - Law360
Goldman Sachs maintains AstraZeneca stock with $98 target By Investing.com - Investing.com UK
Goldman Sachs lifts AstraZeneca stock target, sees growth By Investing.com - Investing.com UK
AstraZeneca Fights Generic Diabetes Drug Launch - Law360
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance
Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com
Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360
J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business
J&J’s Rybrevant-Lazcluze Combo Tops AstraZeneca’s Drug in EGFR Lung CancerJohnson & Johnson (NYSE:JNJ) - Benzinga
Astrazeneca PLC (AZN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):